Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:10
  • preuzimanja u poslednjih 30 dana:9
članak: 5 od 31  
Back povratak na rezultate
Vojnosanitetski pregled
2017, vol. 74, br. 8, str. 722-727
jezik rada: engleski
vrsta rada: izvorni naučni članak
doi:10.2298/VSP151209261C
Creative Commons License 4.0
Neurofiziološka procena kratkoročnog ishoda farmakološkog lečenja dijabetesne neuropatije
aClinical Center of Vojvodina, Neurology Clinic, Novi Sad + University of Novi Sad, Faculty of Medicine, Novi Sad
bMilitary Medical Academy, Neurology Clinic, Belgrade + University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade

e-adresa: emgnscvij@gmail.com

Sažetak

Uvod/Cilj. Dijabetesna polineuropatija (DPN) je veoma česta, progredijentna bolest koja dovodi do grubog urušavanja kvaliteta života praćenog visokom stopom invalidnosti. Iz tih razloga ispitivanje terapijskih sredstava za ovu bolest je u zamahu. Metode. Ispitivani su najčešće korišćeni lekovi za dijabetesnu neuropatiju u našem podneblju, uz elektrofiziološko praćenje da bi se izbegla subjektivnost i “placebo efekat”. Kod ukupno 120 bolesnika podeljenih u četiri grupe ispitivana je alfa lipoinska kiselina, benfotiamin i gabapentin, s tim što je elektrofiziološki praćena i grupa bolesnika koji u posmatranom periodu nisu dobijali terapiju. Analizirali smo motornu brzinu provođenja, distalnu latencu, senzitivnu brzinu provođenja, F talas i hronodisperziju F talasa, pre i posle terapije za svako pojedinačno terapijsko sredstvo. Rezultati. Evidentno je da su neki lekovi imali povoljan uticaj na stanje perifernog nerva. Alfa lipoinska kiselina i benfotiamini su imali uticaja na oporavak nerva odnosno patofiziološke procese, gabapentin je bio bez uticaja na oporavak, a slično je bilo i kod kontrolne grupe koja je bila bez bilo kakve terapije. Elektrofiziološki pokazatelji su imali različitu osetljivost na detekciju stanja perifernog neurona. Najbolji efekat koji se ogleda u povećanju senzitivne brzine provođenja imali su bolesnici koji su tretirani alfalipoičnom kiselinom. Zaključak. Uticaj alfa lipoinske kiselina i benfotiamina na stanje perifernog nerva je evidentno. Odsustvo oporavka, odnosno pogoršanje elektrofizioloških pokazatelja kod ispitanika koji nisu dobijali neuroprotektivnu terapiju, ukazuje na potrebu permanentne medikacije i periodičnog elektrofiziološkog praćenja bolesnika sa dijabetesnom polineuropatijom.

Ključne reči

Reference

American Diabetes Association (2012) Standards of medical care in diabetes: 2012. Diabetes Care, 35 Suppl 1: S11-63
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., Nurmikko, T. (2010) EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology, 17(9): 1113-e88
Callaghan, B.C., Little, A.A., Feldman, E.L., Hughes, R.A. (2012) Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews
Cryer, P. E. (1993) Hypoglycemia Begets Hypoglycemia in IDDM. Diabetes, 42(12): 1691-1693
Dworkin, R.H., o`Connor Alec, B., Backonja, M., Farrar, J.T., Finnerup, N.B., Jensen, T.S., Kalso, E.A., Loeser, J.D., Miaskowski, C., Nurmikko, T.J., Portenoy, R.K., Rice, A.S.C., Stacey, B.R., Treed (2007) Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain, 132(3): 237-251
Đorđević, G., Đurić, S., Apostolski, S., Đorđević, V., Živković, M. (2008) Total antioxidant blood capacity in patients with type 2 diabetes mellitus and distal symmetrical polyneuropathy. Vojnosanitetski pregled, vol. 65, br. 9, str. 663-669
Ewing, D. J., Clarke, B. F. (1986) Diabetic Autonomic Neuropathy: Present Insights and Future Prospects. Diabetes Care, 9(6): 648-665
Fraser, D. A., Diep, L. M., Hovden, I. A., Nilsen, K. B., Sveen, K. A., Seljeflot, I., Hanssen, K. F. (2012) The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes: A 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care, 35(5): 1095-1097
Greene, D.A., Stevens, M.J., Feldman, E.L. (1999) Glycemic control. u: Dyck P.J.; Thomas P.K. [ur.] Diabetic Neuropathy, Philadelphia: WB Saunders, 297-315, 2nd ed
Hammes, H., du Xueliang,, Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D., Neumaier, M., Bergfeld, R., Giardino, I., Brownlee, M. (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med, 9(3): 294-9
Hotta, N., Toyota, T., Matsuoka, K., Shigeta, Y., Kikkawa, R., Kaneko, T., Takahashi, A., Sugimura, K., Koike, Y., Ishii, J., Sakamoto, N. (2001) Clinical Efficacy of Fidarestat, a Novel Aldose Reductase Inhibitor, for Diabetic Peripheral Neuropathy: A 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care, 24(10): 1776-1782
Mijnhout, G.S., Alkhalaf, A., Kleefstra, N., Bilo, H.J. (2010) Alpha lipoic acid: A new treatment for neuropathic pain in patients with diabetes?. Neth J Med, 68(4); 158-62
Pluijms, W., Huygen, F., Cheng, J., Mekhail, N., van Kleef, M., van Zundert, J., i dr. (2011) Evidence-based interventional pain medicine according to clinical diagnoses. 18. Painful diabetic polyneuropathy. Pain Pract, 11(2):191-8
Schreeb, K.H., Freudenthaler, S., Vormfelde, S.V., Gundert-Remy, U., Gleiter, C.H. (1997) Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate. Eur J Clin Pharmacol, 52(4); 319-20
Somani, R., Shaikh, A. (2010) Animal models and biomarkers of neuropathy in diabetic rodents. Indian Journal of Pharmacology, 42(3): 129
Stracke, H., Gaus, W., Achenbach, U., Federlin, K., Bretzel, R.G. (2008) Benfotiamine in Diabetic Polyneuropathy (BENDIP): Results of a Randomised, Double Blind, Placebo-controlled Clinical Study. Experimental and Clinical Endocrinology & Diabetes, 116(10): 600
Vallianou, N., Evangelopoulos, A., Koutalas, P. (2009) Alpha-Lipoic Acid and Diabetic Neuropathy. Review of Diabetic Studies, 6(4): 230-236
Várkonyi, T., Putz, Z., Keresztes, K., Martos, T., Lengyel, C., Stirban, A., i dr. (2013) Current options and perspectives in the treatment of diabetic neuropathy. Curr Pharm Des, 19(27); 4981-5007
Vinik, A. (2003) Management of neuropathy and foot problems in diabetic patients. Clinical Cornerstone, 5(2): 38-55
Vinik, A.I., Mitchell, B.D., Leichter, S.B., Wagner, A.L., o`Brien J.T., Georges, L.P. (1995) Epidemiology of the complications of diabetes. u: Leslie R.D.; Robbins D.C. [ur.] Diabetes Clinical Science in Practice, Cambridge, UK: Cambridge University Press, 221-287
Ziegler, D., Ametov, A., Barinov, A., Dyck, P.J., Gurieva, I., Low, P.A., Munzel, U., Yakhno, N., Raz, I., Novosadova, M., Maus, J., Samigullin, R. (2006) Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The Sydney 2 trial. Diabetes Care, 29(11): 2365-2370
Ziegler, D., Sohr, C. G.H., Nourooz-Zadeh, J. (2004) Oxidative Stress and Antioxidant Defense in Relation to the Severity of Diabetic Polyneuropathy and Cardiovascular Autonomic Neuropathy. Diabetes Care, 27(9): 2178-2183
Ziegler, D. (2004) Thioctic Acid for Patients with Symptomatic Diabetic Polyneuropathy. Treatments in Endocrinology, 3(3): 173-189